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Abstract 
Background: The role of age as a prognostic factor has been examined in single institutional studies and in larger 
data sets from the SEER database, showing a survival advantage for younger versus adult patients with synovial sar-
coma (SS). To further assess the role of age, socioeconomic status and other prognostic factors on outcome for SS, we 
analysed a contemporary all-age population-based cohort of patients with SS registered in England.
Methods: The data on 1318 synovial sarcomas diagnosed in England between 1985 and 2009 were retrospectively 
analysed for incidence, and the effect of age, patient characteristics and deprivation on outcome using both univari-
ate and multivariate analysis.
Results: The incidence of SS increased to 1.4 per million over the time period, the numbers diagnosed in patients 
under 10 years of age were small. The site or incidence of metastases did not vary between age groups. There were, 
however, significant differences (p < 0.05) in the 5-year relative survival rates between patients aged 0–19 years and 
those ≥20 years of age, 76 % and 53 % respectively. Survival was better in localised tumours at an extremity site. In 
multivariate analysis higher mortality occurred in older patients, non-extremity site, presence of metastases, female 
adults and a higher deprivation score.
Conclusions: Synovial sarcoma in children/teenagers compared with adults, have a similar clinical presentation in 
this population-based series, but a superior outcome. The finding of socioeconomic deprivation affecting outcome in 
SS needs further exploration in a complete and contemporary dataset, where all prognostic variables are present.
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Background
In childhood and adolescence synovial sarcoma (SS) 
is rare with an annual incidence of 0.5 per million and 
only six new cases per year diagnosed in those less than 
15 years of age in the UK [1]. The incidence, however, of 
SS differs across age groups. In the North American pop-
ulation-based surveillance epidemiology, and end results 
(SEER) cancer registry, the age-standardised incidence 
of SS was higher in adults at 1.42 per million [2] versus 
0.81 per million in patients under 19  years of age [2]. 
Recorded incidence may have changed over time due to 
more accurate diagnosis, with the recognition of a char-
acteristic translocation involving chromosome 18 and X, 
resulting in the detection of one of several types of fusion 
genes (SYT-SSX1, 2 and 4) in 90 % of cases [3, 4].
Surgery remains an important aspect of treatment for 
localised SS with radiation, which may facilitate surgical 
resection [5]. In paediatric practice, less radiotherapy is 
used in view of late effects [21]. The role of chemother-
apy in SS is not completely defined, but is used more in 
paediatric patients [6, 7]. In adults, chemotherapy is not 
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standard of care, particularly in localised disease regard-
less of tumour size, but is used in high-risk patients and 
those with metastases [8] or as part of investigational tri-
als [9].
The role of age as a prognostic factor has been exam-
ined in single-institutional studies and the SEER data-
base; Ferrari et  al. demonstrated that children had a 
better outcome than adults, asserting but not prov-
ing that this was due to the use of more chemother-
apy [10]. Socioeconomic status has been shown to be 
a significant predictor of outcome in lung, colon and 
breast cancer, with those patients with lower socio-
economic status having a worse outcome [11–13]. The 
effect of socioeconomic status on the outcome of SS 
has not been studied. To further assess the role of age, 
socioeconomic status and other prognostic factors on 
outcome for SS, we analysed a contemporary all-age 
population-based cohort of patients with SS registered 
in England.
Methods
This study carried out a retrospective population-based 
analysis of the incidence, clinical characteristics, and sur-
vival of SS.
Source of data
The anonymised data were extracted from the National 
Cancer Data Repository (NCDR), a compilation of data 
collected by all regional cancer registry offices in Eng-
land. The information includes age, sex, ethnicity, post 
code of residence, anatomical site of tumour, and some 
treatment data. Two different versions of the NCDR were 
utilised for the analyses. Incidence and survival data was 
utilised from the 1985–2009 version of the NCDR—con-
taining 1318  SS. The 1990–2010 NCDR was utilised so 
that treatment data could be assessed as recently as pos-
sible, with 70 SS diagnosed in 2010.
All SS diagnosed in England between 1985 and 2009 
classified by the 10th revision of the International Clas-
sification of Diseases (ICD-10 site code) and Interna-
tional Classification of Disease for Oncology, version 3 
(ICD-0-3) morphology codes M9040-9043 were analysed 
[14, 15]. All incidence cases identified were included in 
the analysis except for four death certificate only (DCO) 
cases which were excluded for the purpose of survival 
analyses. This is in line with the recommended practice 
of data quality for conducting survival analyses [28] and 
none of the other quality controls were relevant to this 
cohort. Death certificates are provided by the Office of 
National Statistics (ONS).
Morphology subtype was not analysed since 1107 
(84  %) of the 1318 patients were recorded as having SS 
not otherwise specified (NOS) [M9040].
Hospital Episode Statistics (HES) data is a record of all 
hospital admissions. HES data captures information on 
admission date, operations and procedures, and other 
co-morbidities. HES data was linked to the NCDR on the 
patient demographics—NHS number, date of birth and 
postcode.
Patient ethnicity is described in the analyses although 
not included in any statistics due to the incompleteness 
of this data item.
Metastatic status was derived from the HES data If a 
patient had a diagnosis of ICD-10 codes C77 (Secondary 
and unspecified malignant neoplasm of lymph nodes), 
C78 (Secondary malignant neoplasm of respiratory and 
digestive organs) or C79 (Secondary malignant neoplasm 
of other sites) recorded during an admission within 
4 months following sarcoma diagnosis. OPCS Classifica-
tion of Interventions and Procedures, version 4 (OPCS4) 
codes were extracted from the HES data for SS patients. 
Surgery was classified as the OPCS4 codes which relate 
to radical curative surgery, and occurred within 6 months 
of initial diagnosis. Patients for which no HES record 
could be identified were removed for this set of analyses. 
This resulted in 776 cases out of 819 diagnosed between 
2000 and 2010 available for analysis.
Due to the low incidence of SS occurring outside of the 
extremities, cancer sites were classified as extremity or 
other for the purpose of statistical modelling.
Socioeconomic status
Socioeconomic status was assessed using the income 
domain (ID) of the index of multiple deprivation 2010 
(IMD) [16]. The IMD uses information from the National 
Census to form a score from 7 measures of deprivation 
for a given area: income, employment, health, education, 
crime, access to services, and living environment. The 
scores are assigned to geographic areas within England, 
each with a local population of approximately 1500 so 
that each postal code can be allocated a score. The scores 
range from 1 (least deprived) to 5 (most deprived). For 
reasons of comparability with other parts of the United 
Kingdom, cancer data is analysed with respect to the 
income domain only.
Statistical methods and data analysis
Confidence intervals around incidence rates were calcu-
lated using the gamma method [17]. Significant differ-
ences for the incidence rates were inferred by comparing 
the confidence intervals (CI) for different rates. If the 
confidence intervals overlapped then the rates are not 
significantly different and if the confidence intervals did 
not overlap then the rates are significantly different. A p 
value of <0.05 was considered significant. All statistical 
tests were two-sided.
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Relative survival was defined as the observed survival 
in the patient group divided by the expected survival of 
the general population, matched by age, sex and calen-
dar year. Relative survival was estimated by the Ederer 
II method [18] using the STRS programme in STATA 
(version 13). National life tables were obtained from 
the Cancer Research UK Cancer Survival Group at the 
London School of Hygiene and Tropical Medicine. All 
patients were last followed up on 31 December 2013 
and analysed in 2014. Therefore, patients diagnosed in 
2009 were excluded from survival analyses because of 
lack of 5-year follow-up. Five-year relative survival was 
calculated using 5-year rolling averages. Cox propor-
tional-hazard models were used to identify the prognos-
tic factors most likely to result in death for people with 
SS and were calculated for patients diagnosed between 
2000 and 2010. To assess the role of age as a prognostic 
factor a cut off of 19 years was chosen in view of the data 
from the SEER analysis (2).
Multivariable logistic regression models were used to 
assess the risk of metastases dependent on age at diagno-
sis, sex, site and ID score.
Results
Patient characteristics
Between 1985 and 2009, 1318 SS were registered. Age at 
diagnosis ranged from 8  months to 93  years, with only 
25 cases reported under the age of 10 years. The largest 
numbers and highest age-specific rates occurred in males 
aged 30–34 years. (Fig. 1).
The age-standardised incidence rates (3-year rolling 
average) for all ages combined increased from 0.7 per 
million to 1.4 per million in males and from 0.5 per mil-
lion to 1.4 per million in females between 1985 and 2009, 
with the steepest increase from 1997 onwards.
Among the population between 0 and 19 years the age-
standardised incidence rates fluctuated between 0.08 
per million and 1.1 per million. However, in the 20-years 
and over age group there was a statistically significant 
increase from 0.7 per million in 1985 to 1.4 per million in 
2009 (p < 0.05).
Table 1 describes demographic and clinical character-
istics for all ages combined and for the two age groups 
of 0–19  years and ≥20  years. Univariate analysis of the 
clinical characteristics in Table  1 showed there were no 
differences between children/adolescents and adults (all 
p values >0.07). The commonest site was extremity (65 %) 
followed by soft tissues of the trunk.
Among 776 of 819 patients diagnosed between 2000 
and 2010 for which HES records were identified, whether 
distant metastases were found at diagnosis and whether 
the patient had any surgical intervention in the month 
preceding diagnosis or the 6 months following diagnosis 
were analysed, but there were no significant differences 
between the two age groups for either distant metastases 
or surgical intervention (p > 0.1) (Table 1).
The income domain of the IMD scores were equally 
distributed in the 5 groups, with a non-significant higher 
percentage in the most deprived group (score 5) for the 
0–19 years cohort (all p values >0.06).
Fig. 1 Age specific incidence rates males and females, for the years 1985–2009 in England
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Survival and prognostic factors
There was no significant variation in the 5-year relative 
survival rates for SS over the period 1985–2008, regard-
less of age groups. (Figs.  2, 3). The 5-year relative sur-
vival rate was 56 % [CI: (47–64 %)] for patients diagnosed 
between 1985 and 1989, and 56 % [CI: (51–61 %)] in the 
most recent diagnosis years (2004–2008). There were, 
however, significant differences (p  <  0.05) in the 5-year 
relative survival rates between patients aged 0–19  years 
and those ≥20 years of age, both in years 1985–89 [72 %, 
95 % CI: (46–88 %)] vs. [53 %, 95 % CI: (44–62 %)] and in 
years 2004–08 [76 %, 95 % CI: (63–85 %)] vs. [53 %, 95 % 
CI: (47–58 %)]. (Fig. 3). 
There was no difference in outcome among sex and 
ID of IMD. There was, however, a worse outcome for 
tumours at a non-extremity site compared to tumours 
of the extremity, 5-year relative survival 34  % [95  % CI: 
(27–42  %)] and 71  % [95  % CI: (64–76  %)] respectively, 
p  <  0.001. Metastatic spread was also associated with a 
poorer outcome, 5-year relative survival was 7  % [95  % 
CI: (2, 15 %)] for those with distant metastases and 65 % 
[95 % CI: (59, 70 %)] for those without, p < 0.001.
Table 1 Patient characteristics in 1318 patients with synovial sarcoma
There were no significant differences in the proportions of children or adults having any of the tabulated characteristics
a Based on 2010 data to allow further inclusion of metastases
All patients Children and teenagers Adults
No. % No % No. %
Total 1318 – 182 – 1136 −
Age (years)
 0–9 25 2 25 14 0 0
 10–19 157 12 157 86 0 0
 20–29 237 18 0 0 237 21
 30–39 239 18 0 0 239 21
 40–49 207 16 0 0 207 18
 50–59 189 14 0 0 189 17
 60–69 130 10 0 0 130 11
 ≥ 70 134 10 0 0 134 12
Sex
 Female 628 48 79 43 549 48
 Male 690 52 103 57 587 52
Location
 Head and neck 66 5 14 8 52 5
 Extremity 861 65 114 63 747 66
 Lungs and pleura 60 5 6 3 54 5
 Trunk 190 14 27 15 163 14
 Others 141 11 21 12 120 11
Quintile of the income domain of the index of multiple deprivation 2010
 Least deprived 257 19 36 20 221 19
 2 256 19 30 16 226 20
 3 261 20 29 16 232 20
 4 278 21 41 23 237 21
 Most deprived 266 20 46 25 220 19
Stage at diagnosisa
 Total known 776 109 667
 Localised 656 85 97 89 559 84
 Metastatic 120 15 12 11 108 16
Did patients have surgery?
 Surgically treated 550 71 84 77 466 70
 Not surgically treated 226 29 25 23 201 30
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For all patients in the multivariate analysis, age 
remained significant; the highest mortality was in those 
≥70 years of age with a hazard ratio (HR) of 8.48 relative 
to those aged between 0–19 years (Table 2). For the whole 
population other factors associated with a higher mor-
tality included non-extremity tumour site, female sex, 
Fig. 2 Synovial sarcoma 5-year relative survival rates (5-year rolling average) (England: 1985–2008). LCI lower confidence interval, UCI upper confi-
dence interval
Fig. 3 5-year relative survival rates for synovial sarcoma (5-year rolling average) for the years 1985–2009 in England 0–19 years and 20+ years
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presence of distant metastases and ID score-5 (Table 2). 
For those <20 years of age non-extremity site lost signifi-
cance but the presence of distant metastases remained 
significant. For adults (≥20  years), male sex, presence 
of distant metastases and non-extremity site remained 
significant, with ID of IMD score only just significant. 
(Table  2) It is noteworthy that the number of children/
teenagers <20 years of age was small in this model with 
only 182 in total. We explored possible associations with 
the age at diagnosis and the ID score but did not find any 
significant results in several different groupings of patient 
age at diagnosis.
For patients with extremity SS, they were less likely to 
have distant metastases at diagnosis than those with SS at 
other sites with an odds ratio of 0.67 (p < 0.05). This was 
the only characteristic associated with a decreased risk of 
metastases (Table 3).
Discussion
This analysis of 1318 patients with SS diagnosed from 
1985 to 2009 is the largest population-based study to 
date, including all stages of disease. The unusually large 
numbers for such a rare tumour allowed us to study 
changes in incidence and outcome, the effect of prognos-
tic factors, and uniquely the effect of severe deprivation 
as represented by the ID of the IMD score on outcome. 
We confirmed that age is an important prognostic factor, 
with patients aged 0–19 years having a significantly bet-
ter outcome but severe deprivation does affect outcome. 
As significant is the outcome for elderly patients the 
highest mortality was in those ≥70 years of age. Further-
more, the value of these findings is enhanced due to the 
quality of the national registrations and the high level of 
case ascertainment with minimal serious errors detected 
on regular completeness and validity checks [19].
Table 2 Cox proportional hazards regression for  mortality in  819 patients with  synovial sarcoma diagnosed 
between 2000 and 2010
* Statistically significant at p < 0.05
** Statistically significant at p < 0.01
*** Statistically significant at p < 0.001
a Based on 2010 data to allow further inclusion of metastases
Variable All patients Children and adolescents Adults
Hazard ratio (95 % CI) Hazard ratio (95 % CI) Hazard ratio (95 % CI)
Age category, years
 0–19 1.00 – –
 20–29 1.39 (0.84–2.31) – –
 30–39 1.92 (1.20–3.07)** – –
 40–49 2.12 (1.32–3.43)** – –
 50–59 2.73 (1.68–4.45)*** – –
 60–69 4.98 (3.08–8.05)*** – –
 ≥ 70 8.48 (5.27–13.64)*** – –
Sex
 Female 1.00 1.00 1.00
 Male 0.67 (0.54–0.84)*** 0.95 (0.40–2.23) 0.70 (0.56–0.88)**
Primary site
 Extremity 1.00 1.00 1.00
 Other 2.25 (1.79–2.82)*** 1.73 (0.68–4.36) 2.23 (1.76–2.82)***
Stage at diagnosisa
 Localised 1.00 1.00 1.00
 Metastatic 6.15 (4.75–7.95)*** 42.4 (12.53–143.70)*** 4.86 (3.74–6.33)***
Quintile of the income domain of the index of multiple deprivation 2010
 Least deprived 1.11 (0.78–1.59) 2.39 (0.47–12.19) 1.17 (0.81–1.68)
 2 1.34 (0.95–1.91) 1.68 (0.31–9.16) 1.33 (0.93–1.90)
 3 1.00 1.00 1.00
 4 1.18 (0.83–1.68) 0.61 (0.13–2.83) 1.22 (0.84–1.76)
Most deprived 1.48 (1.03–2.12)* 2.35 (0.54–10.16) 1.27 (0.88–1.84)
Time varying covariate
 Primary site 0.76 (0.64–0.91)** – 0.73 (0.61–0.88)**
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There are, however, limitations to this study. Although 
data are available on the presence of metastases or not 
at diagnosis, which was similar in the two age groups, 
0–19  years and ≥20  years, other factors explaining the 
better outcome in the younger age group, are missing. 
Data on tumour size, biology, chemotherapy and radio-
therapy, were not routinely collected by the cancer regis-
tries in England until 2013. Therefore, the better outcome 
in children and adolescents maybe due to other factors 
unavailable in this series. Lastly, 77 % of children/adoles-
cents and 70 % of adults were recorded as having surgery, 
compared with 98 and 88 % respectively in the SEER study 
[2], suggesting that surgery is incompletely recorded.
Two roughly contemporary Italian hospital-based 
series have contrasting results. At the Instituto Tumori, 
Milan, among the 255 patients with localised disease, 
more chemotherapy was given to younger patients sug-
gesting that this accounted for their better outcome 
[10]. At Rizzoli, however, among patients with localised 
disease there was no difference in chemotherapy usage 
between age groups, but children had better survival than 
adults [22]. The lack of effect of treatment in particular 
chemotherapy has also been confirmed in a recent Neth-
erlands cancer registry study in localised SS, furthermore 
they demonstrate that younger age is again important for 
outcome regardless of site or tumour size. [25].
The better outcome in children/adolescents compared 
to adults with SS was also found in the analysis of the 
SEER data [2]. Other similarities in our study included 
similar clinical presentation between adults and children/
adolescents in terms of metastases and the site of the 
tumour. Our study also confirmed that those with limb 
primaries and no metastases had a superior outcome [2]. 
Poor outcome in SS arising in non-limb sites has also 
been demonstrated in a smaller Italian series and the 
SIOP MMT analysis [20, 21]. A possible explanation for 
the better outcome in younger patients with SS is biology, 
in particular the role of genomic index (GI) [26]. Increas-
ing genomic instability as scored by GI is more frequent 
in adults compared to children with SS, and predicts for 
metastatic relapse and survival [26]. Furthermore GI is 
independent of response to neoadjuvant chemotherapy 
and remains an independent prognostic factor [27]. This 
factor could not be analysed in our series, and needs con-
firming in a prospective trial.
The overall 5-year relative survival at 57  % compared 
favourably with similar population-based series, in par-
ticular the SEER database [2]. Compared with series, 
which are institutionally based, our outcome seems 
superior, but it is likely that institutional series reflect a 
higher risk group, and contains patients from an earlier 
time period [10, 22]. It is disappointing that over time the 
survival in England has not improved. Recent paediat-
ric series from the European Paediatric soft tissue group 
have a much better outcome, but they only included 
young patients with localised disease [24].
A novel feature of this study was the ability to assess the 
role of deprivation on outcome using the income domain 
of the Indices of Multiple Deprivation 2010. ID scores have 
been widely used to study the relationship between socio-
economic factors and outcome in cancer [11–13]. These 
studies demonstrated a worse outcome among patients 
with more deprivation and higher deprivation scores. For 
the whole cohort in our study, patients with the highest ID 
Table 3 Multivariable logistic regression to assess the relative risk of being diagnosed with distant metastases depend-
ent on age at diagnosis, sex, site and ID score in 819 patients with synovial sarcoma diagnosed between 2000 and 2010
* Statistically significant at p < 0.05
*** Statistically significant at p < 0.001
Variable Odds ratio (95 % CI)
Age 20–29 1.31 (0.60–2.83)
Age 30–39 2.14 (1.03–4.43)*
Age 40–49 1.20 (0.55–2.65)
Age 50–59 1.68 (0.76–3.71)
Age 60–69 1.57 (0.67–3.67)
Age 70+ 1.52 (0.64–3.62)
Sex (male) 0.72 (0.49–1.08)
Primary site (extremity) 0.66 (0.49–0.98)*
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of IMD score 5 only, and hence the most deprived, had a 
worse outcome, this held in the adult cohort but was not 
significant in the younger age group, possible due the 
small numbers <19 years of age. This may be plausibly due 
to diagnostic delays (professional or patient), or to poor 
awareness of this tumour, but the lack of data on tumour 
size, treatment received and length of clinical pathway 
hampers any further interpretation. However, the ID score 
did not predict for increased metastases at diagnosis. The 
role of deprivation on survival from SS has not been stud-
ied previously, but in Ewing sarcoma survival was signifi-
cantly lower in deprived groups [23].
Conclusion
Children/teenagers and adults with SS have a similar 
clinical presentation but children/teenagers have a supe-
rior outcome. The lack of complete data on treatment 
received makes it impossible to tell whether this or bio-
logical variables explain this difference, though the lat-
ter is more likely. The finding of severe socioeconomic 
deprivation as presented as the ID of IMD score affecting 
outcome in SS needs further exploration in a complete 
and contemporary dataset, where all prognostic variables 
are present. This may be possible in the current national 
cancer registry. The paucity of all-ages, large and interna-
tional randomised studies in SS, with the testing of new 
targeted agents, may have contributed to the static out-
come in this cohort over this time period.
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